The potential for growth is enormous here with the added incentive of Roche involvement

Osmetech wins $700,000 sales deal in China
By Marianne Brun-Rovet
Published: April 29 2003 12:07 | Last Updated: April 29 2003 12:07


Osmetech, the manufacturer of "electronic nose" sensors for healthcare applications, has secured a sales deal with China to assess Sars patients.


The deal, worth an initial $700,000, will use Osmetech's OPTI blood gas analysers to aid in the monitoring of Sars, which has so far infected more than 2,000 people in China.

James White, chief executive, said the deal with China was "a bit of a moving feast" as the government increased orders by the day. "There has been some interest from other governments in the region but there is much uncertainty."

The OPTI analysers are portable instruments incorporating optical sensors for blood gas, electrolyte and metabolite analysis. One of the instruments can be used for measuring the oxygen saturation and acid-base balance in Sars patients. Osmetech said this would be particularly useful in cases where treatment required the use of a ventilator of supplemental oxygen therapy.

The instrument can also be used to detect blood gas variations that frequently occur in Sars patients, but Osmetech said it was not a diagnostic tool. Osmetech acquired Roche's Atlanta-based OPTI product line of blood gas analysers in a deal worth $3.5m three weeks ago.
Tris

loafy..Of the approximately 500 million in circulation that a good 20% of the Co traded now .
Tris

( BW)(OSMETECH)(OMH.L) Demand from China Rises for Osmetech Portable Device For Assessment of SARS Patients

Business Editors

ATLANTA--(BUSINESS WIRE)--April 30, 2003--Osmetech plc (OMH: L) reports a sharp increase in sales in China for its Osmetech OPTI Critical Care Analyzer (CCA) blood gas analyzer, which makes it possible to determine quickly if a SARS patient is likely to experience respiratory distress that can prove fatal if not discovered in time.
Osmetech, a developer of medical diagnostics devices in the U.K. and U.S., acquired the manufacturer of the OPTI CCA instruments in early April. Orders received last week from China totaled $700,000, about the same volume the company originally projected globally for the entire month of April.

The Osmetech OPTI CCA, made in Atlanta, is about the size of a briefcase, is portable and very robust. It incorporates optical sensors for blood gas, electrolyte and metabolite analysis that can aid in monitoring patients with Severe Acute Respiratory Syndrome (SARS). The system is simple to use, allowing physicians to get the results they need quickly without having to send blood samples out to a lab. Chinese authorities have waived traditional import restrictions and paperwork to allow healthcare professionals access to OPTI instruments.
While no definitive diagnostic test is currently available for SARS, the Osmetech OPTI CCA helps determine if a SARS patient is likely to experience respiratory distress, giving the physician additional time to adjust the medical treatment protocol and monitor the patient's response to therapy. The onset of hypoxemia is usually apparent in the latent stages of the illness. It is important to closely monitor these critical blood gas parameters and quickly adjust treatment as needed for optimal outcome of SARS infected patients.
The Osmetech OPTI CCA's test panel can be effectively utilized to detect blood gas variations that frequently occur in SARS patients. It is particularly of value in SARS cases where a ventilator or supplemental oxygen therapy must be employed to aid in patient treatment and in cases where doctors need to take frequent blood samples and establish a trend.
Osmetech - founded in the U.K. in 1994 and known as the world's leading manufacturer of electronic nose sensors for the detection of micro-organisms such as infectious bacteria, fungi and moulds -- acquired the OPTI blood gas analysis product line from Roche at the start of April 3, 2003 for about $3.5 million. Osmetech Plc. has retained True North Capital as an advisor to provide assistance with U.S. and European business development.

With over 100 million shares traded in the last two days (not including today) the vast majority buys at or around 3.5p there must be a few disgruntled at the tree shake this am, especially if you were one that fell out the tree :0)coming back nicely now though, dont let the MMs have their way, imho this will do well medium to long term. But do do your own research.
Tris

Must admit I'm getting a bit despondant, price drops when there is selling, price drops when there is buying, more than a little confused but I intend to stick it out, as you have said "there can't be many left". Did I read somewhere that gaps are always eventually filled, well the "gap up" on Tues morning was filled today, maybe some progress tomorrow! -:))

Hi Tris

omh swinging wildly MMs must be having a ball ....... up 6% down 4% up 5% then all Sq now UP again....the buys seem to be coming back in @ 3.2p

I see China has reported more SARS deaths this morning and a increase in reported cases ........

"Beijing is likely to continue seeing new cases of Sars at the current high rate of more than 100 a day, a city health chief has said"


http://news.bbc.co.uk/2/hi/asia-pacific/2994533.stm

Hopefully Osmetech's OPTI blood gas analysers will start to stem the tide


Gc

Hi Gc ....yes an unexpected windfall for OMH and looks, as though well see more orders because of the Sars thing.
Have to remember the outlook was ok without this flue thing, as the benefits show for the company lets hope the equipment helps in its eradication.
Tris

World Markets Analysis

May 01, 2003

SECTION: MAIN STORY

LENGTH: 1166 words

HEADLINE: Doubt Over SARS Origin Set to Put Back Development of Treatments

BYLINE: Gareth Leather

BODY:
Speaking after a severe acute respiratory syndrome (SARS) conference was held in Toronto, Canadian doctors have cast doubt on the origins of the SARS virus, a development which is likely to hinder the development of a vaccine.
WMRC Perspective

Significance
Researchers in Canada have discovered that only 40% of SARS patients are infected with the coronavirus, and that some patients who are infected with the coronavirus have not developed SARS.

Implications
If confirmed, this will make the discovery of a vaccine more difficult than originally thought. Scientists do need to know exactly which virus is causing SARS before a vaccine can be developed.

Outlook
The World Health Organisation (WHO) has warned that Beijing is running out of hospital beds, which are needed to isolate SARS patients. The experience from other countries suggests that containing the SARS virus can only be done through the quarantine and isolation of infectees. This underlines the necessity of a vaccine, if China is to contain the virus effectively.


Canadian Doctors Cast Doubt on Cause of SARS

At a conference held in the Canadian city of Toronto, the only city outside of Asia to have had WHO travel warning issued against it (which has since been lifted), a team of Canadian doctors dealing with SARS has cast doubt on the origins of the virus, raising speculation that the development of a vaccine for the virus may take longer than was originally thought. Two weeks ago, it was thought that the cause of SARS had been formally identified, after laboratories in Hong Kong and the United States isolated a new strain of the virus from patients. Researchers in Germany then infected monkeys with the virus, and found that they all developed the same symptoms of SARS. This then satisfied the WHO that the coronavirus was the cause of the virus.

However, doctors from Canada say that only 40% of SARS patients seem to be infected with the coronavirus, and that some patients who are infected with the coronavirus have not subsequently developed SARS. Currently, medical authorities around the world are treating SARS-infected patients with isolation and quarantine. If this policy does not prove effective, a vaccine will be needed to combat the virus. However, for scientists to develop a vaccine, they will first need to know exactly which virus they need to develop a vaccine for.

GSK Boss Warns Vaccine Will Take Years

Jean-Pierre Garnier, the Chief Executive of GlaxoSmithKline (GSK), the world's second-largest pharmaceutical company, has said that his company is stepping up work with rival firms in a bid to develop a vaccine for the SARS virus, but also warned that it will take years before a safe and effective vaccine is developed. Speaking to reporters in a conference call, Garnier said that while normally they would be competing with their rivals to discover a vaccine for the virus, they are now sharing some of the science with their competitors. He did warn, however, that it would take a long time before an effective vaccine became available. He also said that even if the virus is contained in the short term, there was a strong chance that it would come back, and so it was best to start work on a vaccine now. His announcement comes after a meeting of the world's top pharmaceutical companies in the US, after the US government asked for their help in finding a vaccine for the virus.

Some Companies Already Benefiting

While pharmaceutical companies are struggling to find a vaccine for the SARS virus, Osmetech, the UK-based manufacturer of electronic healthcare applications, has announced a deal with the Chinese government to assess SARS patients. The company has so far signed a US$700,000 deal to supply the Chinese government with their OPTI blood gas analysers, an aid which can be used to monitor SARS patients. The Chief Executive of the company, James White, said that while there was much uncertainty, there had also been interest from other countries in Asia. The OPTI analysers are portable instruments, incorporating optical sensors for blood, gas, electrolyte and metabolite analysis, and one of the analysers can be used for measuring the oxygen saturation and acid-base balance in SARS patients.

LOL!

http://uk.biz.yahoo.com/030430/183/dyx2s.html

http://mwprices.ft.com/custom/ft-com/story.asp?guid={168DB72C-7863-4C39-9A47-1EFEC782C143}&source=yahoo1

http://www.ananova.com/news/story/sm_773512.html

Ohhhhh gawd here we go again .......run Tris RUN

lol



Gc

lol Gc I think it must be CLERMAN's LOL ! Dad....you know the type a true
Richard but bigger :0)

Hopeing for a little progress on the run up to next interim report published 3/8/03.
Tris

EXCELLENT FUN, GO BUNNY GO!!!!!!

lol

Pinched this from another OMH thread, makes interesting reading. A little long but well worth a read.

Ever wonder how it is that so many shares can go through and the price barely goes up and then just a few sells and the price goes way down?

The Hundred Billion Dollar Loophole

There's a rule that the market makers use ... a rule that only has less than two hundred words in it ... and that rule allows them to naked short an OTCBB or Pink Sheet stock into oblivion. It allows them to literally create, out of thin air, as many shares as they need, to maintain an orderly market.

"(B) Proprietary short sales

No member shall effect a short sale for its own account in any security unless the member or person associated with a member makes an affirmative determination that the member can borrow the securities or otherwise provide for delivery of the securities by the settlement date. This requirement will not apply to transactions in corporate debt securities, to bona fide market making transactions by a member in securities in which it is registered as a Nasdaq market maker, to bona fide market maker transactions in non-Nasdaq securities in which the market maker publishes a two-sided quotation in an independent quotation medium, or to transactions which result in fully hedged or arbitraged positions."

This rule allows a market maker to create a share in a company by simply taking the money from the buyer and making an electronic entry into their brokers' account, and the broker then electronically credits the buyer with one share of that company.

But several things that no one is aware of take place in this transaction.

1. The buyer thinks that his share actually exists, but unless he or she has read his account agreement very carefully, he won't understand that all he did is give money to someone other than the company and never got any actual proof of ownership. His certificate, presumably, is sitting at the DTCC.

2. The market maker filling the order for one share has the buyer's money, and gave nothing except electronic acknowledgement of receipt of it ... the electronic entry in the buyer's account.

One very important thing to understand here, is that at no point in this process, did the company in which the buyer 'invested' ever get one single dime of the money paid by the buyer for that share. There is a tremendous misconception out there that causes many to assume that when they buy a share of a company's stock, the company gets the money.

This is only true if the buyer is buying an IPO, or a private placement of shares from the company. In any other sale or purchase of a stock by an investor, the company does not even see the money.

This is particularly vexing when one begins to understand what happens in naked shorting situations. Situations where the provision that allows for naked shorting to maintain an orderly market is abused.

Understand that whoever is doing the naked shorting is the one receiving the money. They keep it. For as long as it is convenient to do so. That is where the abuse of the rule comes in.

That rule was created to allow for market makers, who by becoming market makers, agree to 'make a market' in certain stocks. That means that they will sell you a share, or buy a share from you, even if there isn't any available, or there are no other buyers for it. The Market makers' job is at least partly, to provide liquidity to the market. In thinly traded securities, or securities where there is a small public float, the market makers' ability to naked short is crucial to the liquidity of the market in that security.

The abuse takes place when the market maker for whatever reason determines that the market for a particular security has become "disorderly". Too much buying pressure, for instance, can cause a price spike in that security that would have no relationship to the true book value of the security. The market maker then determines that he will naked short to fill orders, knowing that by doing so, the price will not explode on unusually high demand because he can literally issue new shares under this rule. The market maker then waits, with an open naked short position in that stock, until the buying pressure subsides, and he can buy enough shares back at lower prices to cover his naked short position.

The rule does not have any time requirements and that allows for the market maker to keep a naked short position open for potentially years. In reality, until the buying pressure subsides enough for him to buy back at lower prices however many shares he needs to fill previously filled orders that make up his naked short position, it simply stays open, and the money sits in his account.

Someone is going to ask the question, "So, how big are all those naked short positions, anyhow?"

There is another provision that says that the market makers do not have to publish their open naked short positions. Never. At all. All OTCBB and Pink Sheet securities can be naked shorted - indefinitely - by market makers under this rule, and there is no way that an investor can discover if there is an open naked short position in a stock he may be interested in, or even how big that short position is.

So far, the SEC does not see a strong need to correct this situation, either.

[Mostly because the sheep...er, ah...investors are happy to hand their money to MM's without so much of a bleat of protest...everybody sing: please re-fleece me, take my cash, for I don't want it anymore...]

Think about it. There are unlimited amounts of shares that were never authorized or issued by a company made available to the unsuspecting investor. They are authorized and issued by the market makers under this rule, and the company never gets any money from the sale of shares created under this rule.

The temptation to abuse this rule is irresistable. Just do the math. A million naked shorted shares sold by a market maker at 0.01 (one cent) is $10,000 that the market maker keeps in his account, and that the company does not get. At 0.10 (ten cents) the market maker gets to keep $100,000. Now, that is for each million shares that the market maker creates.

Under this rule, if a company and/or a group of shareholders begin to suspect a short position exists in their security, they can not discover this from any published source. The price of the stock remains constant, or goes down, even though there is unusually heavy buying ... buying that goes on for years in some cases.

The company thinks that there is someone illegally shorting their stock in an attempt to ruin the company. The shareholders think that the company is illegally printing shares behind their backs and is scaming them. Eventually, this distrust between the company and it's shareholders becomes so great that investors start selling, or the company, already damaged by a supressed share price, is forced to issue additional shares into the market because other collateral-backed loans can not be made with share prices so suppressed.

This is what the market maker is waiting for ... sometimes for as long as years. In both cases, the market maker eventually gets his naked short position covered, and all it cost was the company's reputation, the shareholders' money, and the SEC's full cooperation by allowing this abuse of the rule.

There is a third situation that the market makers naked short into ... a stock that is a likely prospect for failure. In that case, they just continue naked shorting no matter what, keeping the price suppressed, and eventually the company files for bankruptcy, and ... the company goes out of business, the shareholders lose their investment ... and the market maker keeps the proceeds of his continued naked shorting.

A good question for the SEC would be, "Seeing as how the companies that failed never got the proceeds of the sale of stock over and above their issued and outstanding, but the market makers did, isn't the SEC allowing actual fraud to take place, and condoning it by the creation and continued existance of this rule?"

Like it or not, the SEC has allowed securities fraud to run rampant in the OTCBB and Pink sheet stock markets by simply looking the other way and allowing the market makers to target the OTCBB and Pink sheet markets as a source of huge amounts of cash, literally stolen from investors by the third party creation of shares by an entity other than the the issure - the company.

This rule is nothing less than blanket permission by the SEC for market makers to become the issuers of company stock, no matter what the company's official authorized and issued amounts are.

And that, my friends and fellow investors, is securities fraud on a scale almost beyond comprehension.


[This is why many companies file and get off the Pinks with a NEW ticker, and even then there are plenty of tricks the MM's can use to make out like the bandits they are. Still some accounting must be done to convert shares from one ticker to another and this helps clean things up. If you think naked shorting only happens on rare occasion, first you are fooling yourself and second they could use you at the SEC...pretty sure GED or equivalent is all you'll need...except government keeps cutting their budget so they may not be hiring. Republicans are right, who needs all these darn regulations anyway or folks to enforce 'em...?

from another poster on the light side :0) with thanks.

Osmetech
Remains as: OUTPERFORM
2.6p (12m range: 15.75-1.75p)
Acquisition and company update 5 March 2003

Business:
Development of point of care diagnostic products with a focus on infectious disease

Dr Ceri Morgan
+44 (0) 20 7071 4355
ceri.morgan@evbg.com
Sales: Russell Kerr
+44 (0) 20 7071 4424

Company description
Osmetechs core IP uses polymer sensor array technology to detect
volatile metabolites. It has received FDA approval for two of its
products exploiting this technology. Its recent acquisition has
expanded its product base into blood gas analysers, which are sold
into the same market as the targeted position for its core products.

Market position
Osmetech will be first to market with its POC instrument to screen,
diagnose and differentiate between the five most prevalent vaginal
infections. Prior to the acquisition, OPTI held a 1% share of the
$780m blood gas analyser market.

Asset based deal fits
The assets based deal to acquire the point of care blood gas analyser
product line, OPTI, from Roche introduces strengths into the company.
The deal includes the installed base of blood gas analysers
(approximately 4000), with the associated reagent sales, a manufacturing
facility, and 50 employees comprising sales, marketing and R&D teams.
Clearly a tie up with a major diagnostics company, Roche, is good news
for the company and with Roche expressing first distribution refusal
rights on a handheld device (currently in development with an expected
launch 2005/6) it has a vested interest in the future success of this deal.

Cost saving opportunities
There are a number of synergies with this acquisition in which Osmetech can make a number of cost savings. The associated project costs of the VIP5 (point of care vaginal infection) device are expected to reduce by 25% with its launch expected CYE 2004. Additional 30% savings are expected in the overall group with manufacturing, R&D, sales and marketing integrations.

Market share to be gained
The OPTI line has already established a 1% share of the $780m blood gas
analyser market despite not being the lead product for the two years
under Roches control. With focused attention from Osmetech, we
should expect to see the OPTI line achieve profitability FY04
consequently bringing forward the groups profitability and cash
generation timescales. We expect sales of OPTI to facilitate the sales of
VIP5 product as both products share the same targeted market (hospital
casualty departments). Roche division had a large US presence.
Osmetech therefore gains immediate access into the largest geographical
market for point of care.

Roche stands by deal
Whilst it has been difficult to split out historical data surrounding the
OPTI product line, the commitment from Roche post deal encourages
confidence. The next set of results (FYE April) will be an opportunity to
guide us on the integration progress. We remain optimistic of the
acquisitions success.

The story so far
Historically, Osmetech was an R&D focused company. The core technology is
based upon conducting polymer sensor array technology that allows the
detection of volatile metabolites, (compounds produced when microorganisms
metabolise). The acquisition of the OPTI product line has transformed the
company into a revenue-based company with an R&D division. We now have
earnings visibility.

This origional platform technology has a number of potential applications e.g.
urinary tract infections (UTI), bacterial vaginosis (BV) and pneumonia.
Osmetech believes that both the clinical and economic opportunity is with the
VIP5 product. Osmetechs strategy is to exploit the Point of Care (PoC)/ near
patient diagnostic market specialising in infectious diseases. Point of care is the fastest growing division within the diagnostic market. Moreover, growth of infectious disease testing is estimated to be 2-4x faster than the next growth division.

Osmetech has received FDA approval for two of its devices, UTI and more
recently BV. The BV test is the first component of five within the VIP5 device to gain regulatory approval. We expect regulatory approval for the remaining
tests to be relatively straight forward and expect updates during 2004.
VIP5 Launch of the VIP5 product is expected Q4 04/Q1 05.

The associated 700k development costs with this device are expected to reduce to 500k post acquisition per year. This product will be the first of its kind to reach the market. Of the $19.5 billion diagnostics market, vaginal infections represent an approximate $1.4 billion opportunity.

The VIP5 device is single platform POC instrument which can be used to diagnose and differentiate between five of the most common vaginal infections. It is often difficult to distinguish clinically the difference between the top five infections, thus the patient is often treated blind i.e. without a definitive diagnosis.

This can lead to inappropriate treatments in particular, over prescribing of antibiotics. A near patient diagnostic kit would allow fast diagnosis and thus appropriate treatments with obvious economic benefits.

In the US, the diagnosis and treatment of such infections occur in a number of
settings; the physicians office, specialist clinics, and the large majority in the casualty departments. In the insurance led healthcare system of the US,
casualty departments are primary care centres. Thus unlike in the UK, the first
point of call for many patients with STDs is this department. Due to public
health implications of such infections, once diagnosed (or suspected), the
patient must be treated.

Prior to the acquisition, Osmetech lacked any sales and marketing expertise.
The acquisition has introduced a sales and distribution infrastructure whereby,
because of product synergies (potential use in the same hospital departments)
VIP5 can be sold alongside OPTI.

UTI
We await news regarding a partner for the commercialisation of this product.
The UTI device received FDA 510 (k) approval November 2001 and is aimed at
replacing the current definitive culture based test. Osmetechs device can
provide a 15 minute diagnostic time much reduced from the 24 hour culture
test. Osmetech intends to license out the UTI test and is currently in
discussions with a number of potential partners to manufacture and distribute
the product. We expect Osmetech would sacrifice higher royalty payments for
a larger upfront payment. We have not introduced any anticipated deal within
our current forecasts for this product and await an update from the company.

Roche Divisional Acquisition
The asset based acquisition of the blood gas analysis line (OPTI) from Roche
for $3.5m, gives Osmetech an immediate revenue line and an operational cash
advantage to support its core activities. The accumulative benefit of an R&D,
sales and marketing team with manufacturing facilities, allows substantial cost
savings to be made.

In total 800k savings are expected for the combined group during 2004 FY. Synergies within the R&D and manufacturing divisions are likely to reduce burn related to the VIP5 device by 25%. We have forecast that the OPTI division alone to become operationally profitable in 2004.

As a combined group, we now forecast (CYE) EBITDA positvity 05 (previous 06),
cash generation early 06 (previously 07). To achieve these figures, we are
looking for Osmetech to sell at least 600 analysers per year.

Roche has shown its commitment to the deal. It will invest $1m in Osmetech
via a subscription for new shares. Furthermore, Roche has retained first refusal to distribute the OPTI IV handheld device, a development product, which is expected to come to the market 2005/6. This commitment from a major
diagnostics company is good news for Osmetech and recognition of its
confidence in the success of this acquisition and new product developments.

The products
Blood gas analysers are used to establish the levels of oxygen, carbon dioxide
and bicarbonate in addition to blood pH. The results of which, gives an
indication to the effectiveness of respiration. Such measurements are crucial for diagnostic evaluation and the management (quantifies the patients response to therapeutic intervention) of severely unwell patients e.g. severe respiratory conditions, and ventilated patients.This is a $780m market.

Over 65% of US analysers are found on the intensive care units within
hospitals. We believe such devices should be necessity devices within hospital
respiratory and casualty departments Portable OPTI equipment allows near
patient testing and can easily supply departments outside intensive care. OPTI
has a 5% share in the POC segment of this market so far. We believe there is
more market share to be gained.

Roche acquired its POC OPTI line together with a laboratory based OMNI
blood gas line in 2001. The OPTI line under Roche was used as a closing tool
for sale of the lab line and neglected as a product with its own opportunities.
Approximately 4000 instruments have been placed in hospitals. This installed
base has also been acquired by Osmetech. Within the first year of the
integration, Osmetech has forecast 33% sales of new instruments (capital
equipment purchases, not placed) and 66% sales of the consumables. We
would expect the ratio to weight more in favour of consumables after the
transition year.

It is difficult to gauge the growth of this acquisition since it has
been split away from a combined cost and revenue base. However, we can
safely assume revenues from the installed analyser base and receive confidence
that Roche, with a vested interest in its success, has not simply walked away
from this business.

Thanks K

M

Interesting post from another site....hope he wont mind ( rob molloy - 12 May'03)

There is no disguising an element of good fortune for Osmetech in the way the SARS panic has boosted sales of the new OPTI acquisition. The management, though, can claim some credit. Chief executive James White and his board obviously found a promising revenue-generating opportunity when they agreed to buy OPTI.
It has always looked a good, low-cost acquisition. Before the SARS revenue boost, it looked as if the purchase could be pretty much self-financing in the first year. It cost $3.5m before Roche ploughed $1m back into buying 21.8m (4.4%) Osmo shares at around 2.8p each. The prospective annual revenue of $7.5m will be boosted significantly by the orders from the SARS panic which will have cleared stocks.
Cash should come in quickly. The Chinese have been waiving usual bureaucratic nonsense in an effort to get as many of the machines into the country as quickly as possible. The $700,000 sales reported now could be the first of a nice little boom. Other Asian countries are potential buyers, and there must be more to come around the world. Crucially, a good chunk of the order comes in the form of consumables. Some 2/3 of OPTI's annual revenues are in consumables, so anything which boosts the population of machines should generate an improved repeat flow of consumables. The panic has obviously boosted consumption of consumables in the established community of machines.
There appear to be no problems in producing machines to meet orders.They are used in emergency rooms, critical care, and operating rooms, and require relatively little training for the operators.
OPTI is clearly set to build a valuable ongoing revenue stream for Osmo, cutting back the cash burn as development of the eletronic nose devices continues. Follow-up tests continue encouraging, and there appears to be no significant rival product out there. It is important, however, to bundfle several tests into one in order to establish maxiumum penetration of the bv device.
The estimate of a pre-tax loss of 3.2m for the year to April 2003 is unchanged, but the estimate of a loss of 2.6m for the current year is "under revision".
originally written by M. Walters 09/05 and taken from the MWBB.

What I cannot understand is despite all this apparent good news for OMH we still see the stock falling in value. Why, when thre is so much to look forward to , is this the case? I bought on the 14/4/03 at between 2.48 and 2.55 and have seen the bid price according to selftrade drop back to 2.5 today

Whats everyones view on this stock now? Has it peaked or is there any good news to come? The price has fallen rapidly of late! Getting a bit worried as i'm in at 3.05!